Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

20 of 25 arms with a reported figure. Choose arms to narrow the chart.

Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source). objective response rate: 35.6%, ASCO 2026

Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source). objective response rate: 46.9%, ASCO 2026; post hoc

REM-422 24 mg. objective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)

Lenvatinib (off Label) 24 mg. objective response rate: 15.6%, primary analysis

Lenvatinib (off Label) 24 mg. objective response rate: 11.5%, primary analysis

Lenvatinib (off Label) not stated in source. objective response rate: 6%, ASCO 2023 (search record)

Axitinib (off Label) 5 mg. objective response rate: 0%, primary analysis

Axitinib (off Label) axitinib 5 mg twice daily + avelumab. confirmed objective response rate: 18%, primary analysis

Rivoceranib 700 mg. objective response rate (investigator): 15.3%, primary analysis

Rivoceranib 700 mg. objective response rate (independent review): 9.7%, primary analysis

Counts, not percents 5

  • RGT-61159 at or below RP2D (mixed doses). partial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending
  • Osugacestat (AL101, BMS-906024) 4 mg. responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024
  • Osugacestat (AL101, BMS-906024) 6 mg. responders (CR or PR): 2 patients (of 42), final
  • Amivantamab not stated in source. responders: 1 patients (of 21), results posted 05.08.2026
  • Regorafenib (off Label) not stated in source. responders (CR or PR): 1 patients (of 38), results posted 09.10.2025

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.